Answers are grounded in this paper and cite their sources.
Aim: to summarize current clinical guidelines and meta-analyses data, and to present the main statements of the Expert Council of the Russian Gastroenterological Association regarding the optimization of endoscopic diagnosis, morphological verification, pharmacotherapy, and management strategies for patients with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Key points. In the Russian Federation, GERD is a highly prevalent disease: according to a meta-analysis involving over 30,000 individuals, the frequency of heartburn and/or regurgitation occurring once a week or more is 25 %. Proton pump inhibitors (PPIs) represent the cornerstone drug class for the treatment of GERD. Rebamipide targets altered epithelial permeability and mucosal inflammation. Combination therapy with PPIs and rebamipide improves symptoms in patients with non-erosive reflux disease, leading to positive morphological changes in the esophageal mucosa and improved control of nocturnal esophageal acid exposure. Ursodeoxycholic acid (UDCA) may be added to GERD therapy in the presence of biliary reflux or reflux gastritis. The clinical significance of GERD is determined not only by its high prevalence, chronic relapsing course, and impaired quality of life, but also by its precancerous potential. In individuals with GERD, the prevalence of Barrett’s esophagus is approximately 7 %, while the incidence of adenocarcinoma and/or high-grade dysplasia in the presence of low-grade dysplasia is 1.73% annually. Risk factors for the development of Barrett’s esophagus include male sex, age over 50 years, frequent GERD symptoms, tobacco smoking, obesity, and a positive family history. The management of patients with Barrett’s esophagus requires strict adherence to endoscopic and histological diagnostic protocols. Long-term PPI pharmacotherapy remains the standard of chemoprevention against neoplastic progression, demonstrating superiority over surgical treatment. Timely screening of high-risk individuals and adherence to endoscopic surveillance intervals enable the detection of dysplasia and esophageal adenocarcinoma at early, treatable stages. Conclusion. The Expert Council members proposed algorithms for the treatment of acute GERD exacerbation and maintenance therapy, as well as for the diagnosis and surveillance of patients with Barrett’s esophagus, taking into account current evidence and principles of evidence-based medicine. The literature review and the proposed algorithms aim to provide informational support for general practitioners, internists, gastroenterologists, and endoscopists in order to improve the quality of healthcare delivery and ensure effective prevention of esophageal adenocarcinoma.
No takes yet. Share an insight, caveat, or question.
Ivashkin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: